- ICH GCP
- US Clinical Trials Registry
- Klinisk forsøg NCT00721747
Taxotere®, Followed by Myocet® and Cyclophosphamide First Line Treatment in HER2 Neg Breast Cancer
Phase II, Open, Not Randomized Clinical Trial, to Evaluate the Sequential Taxotere®, Followed by Myocet® and Cyclophosphamide First Line Treatment in her2 Negative Breast Cancer Patients
Studieoversigt
Status
Betingelser
Intervention / Behandling
Detaljeret beskrivelse
Phase II, open, not randomized clinical trial, to evaluate the sequential Taxotere®, followed by Myocet® and Cyclophosphamide first line treatment in her2 negative breast cancer patients.
The purpose of this study is to determine how many pathological complete responses are achieved in patients treated with taxotere® (T) followed by Myocet® (M)and Cyclophosphamide (MC) first line treatment in HER2 negative brest cancer patients.
Undersøgelsestype
Tilmelding (Forventet)
Fase
- Fase 2
Kontakter og lokationer
Studiesteder
-
-
Barcelona
-
L'Hospitalet de Llobregat, Barcelona, Spanien, 08906
- Hospital de Hospitalet
-
-
Galicia
-
La Coruña, Galicia, Spanien, 15006
- Hospital Juan Canalejo
-
La Coruña, Galicia, Spanien, 15009
- Centro Oncológico de Galicia
-
Ourense, Galicia, Spanien, 32005
- Complejo Hospitalario de Ourense
-
Santiago de Compostela, Galicia, Spanien, 15706
- Hospital Clinico Universitario de Santiago
-
Vigo, Galicia, Spanien, 36204
- Hospital Xeral Cíes
-
-
Deltagelseskriterier
Berettigelseskriterier
Aldre berettiget til at studere
Tager imod sunde frivillige
Køn, der er berettiget til at studere
Beskrivelse
Inclusion Criteria:
- Brest adenocarcinoma stages II/III
- Female
- Informed consent signed
- HER2 negative
- Age>18 years old
- ECOG < 1
Proper organic function regarding the following criteria:
- ANC > 2,0 x 109L, platelets > 100 x 109L and hemoglobin > 10g/dL (transfusion is allowed)
- Hepatic Function:
i.Bilirubin < 1,5 x UNL ii.AST ,ALT < 2,5 x UNL iii.Alkaline phosphatase < 5 UNL iv.Patients with AST and /or ALT > 1.5 x UNL and alkaline phosphatase > 2.5 x UNL will not be selected for the study c.Renal function: creatinine < 1,25 x UNL, or creatinine clearance > 60 mL/min d.Normal Cardiac function, confirmed with FEVI >50% and electrocardiogram.
- Patients should be available for treatment and follow up and must be treated in investigator or co-investigator site
- Negative pregnancy test(performed 7 days before treatment)
Exclusion Criteria:
- Previous treatment for breast cancer (CT, RT, IT, HT)
- Stages IIIb, IIIc or IV or invasive bilateral breast cancer
- Previous neoplasias treated with Anthracyclines or Taxanes (Paclitaxel or Docetaxel)
- Pregnant or breastfeeding females
- Neurotoxicity Grade 2
- FEV≤50% or any cardiac disease in which anthracyclines are contraindicated
- Other severe diseases regarding investigator criteria
- Any neurological or psychiatric pathology
Previous neoplasia different from breast cancer except:
- skin cancer(no melanoma)
- In situ cervix Carcinoma
- Ipsilateral in situ ductal carcinoma
- In situ lobular in situ carcinoma
- Any other carcinoma without evidence disease in last 10 years
- Treatment chronic with corticoids (except patients starting 6 months before inclusion with low dosages (* 20 mg methylprednisolone or equivalent)
- Concomitant treatment with Hormone ovarian replacement therapy
- Contraindication for corticoids
- Concomitant treatment with another investigational drugs
- Included in another clinical trial with any drug in 30 days before inclusion study
- Concomitant treatment with another anticancer therapy
- Male patients
- Hypersensibility to any study drug or components
Studieplan
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
- Primært formål: Behandling
- Tildeling: N/A
- Interventionel model: Enkelt gruppeopgave
- Maskning: Ingen (Åben etiket)
Våben og indgreb
Deltagergruppe / Arm |
Intervention / Behandling |
---|---|
Eksperimentel: Unique arm
4 cycles of Docetaxel 100mg/m2 iv followed by 4 cycles of Liposomal doxorubicine 60mg/m2/iv and Cyclophosphamide 600mg/m2/iv
|
4 cycles of Docetaxel 100mg/m2 iv followed by 4 cycles of Liposomal doxorubicine 60mg/m2/iv and Cyclophosphamide 600mg/m2/iv
|
Hvad måler undersøgelsen?
Primære resultatmål
Resultatmål |
Tidsramme |
---|---|
Determine proportion of Pathological complete responses
Tidsramme: At the end of the treatment, after Surgery.
|
At the end of the treatment, after Surgery.
|
Sekundære resultatmål
Resultatmål |
Tidsramme |
---|---|
Determine proportion of clinical responses
Tidsramme: At the end of the treatment
|
At the end of the treatment
|
Describe treatment safety
Tidsramme: At the end of the treatment
|
At the end of the treatment
|
Determine proportion of conservative breast surgery
Tidsramme: At the end of the study
|
At the end of the study
|
Evaluate disease free survival
Tidsramme: At the end of the treatment
|
At the end of the treatment
|
Evaluate Overall survival
Tidsramme: At the end of the treatment
|
At the end of the treatment
|
Evaluate gene patterns regarding prediction of treatment response
Tidsramme: At the end of the treatment
|
At the end of the treatment
|
Samarbejdspartnere og efterforskere
Sponsor
Samarbejdspartnere
Efterforskere
- Ledende efterforsker: Jesús García Mata, MD, Grupo Oncológico Gallego
Datoer for undersøgelser
Studer store datoer
Studiestart
Primær færdiggørelse (Faktiske)
Studieafslutning (Forventet)
Datoer for studieregistrering
Først indsendt
Først indsendt, der opfyldte QC-kriterier
Først opslået (Skøn)
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Skøn)
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidst verificeret
Mere information
Begreber relateret til denne undersøgelse
Yderligere relevante MeSH-vilkår
- Hudsygdomme
- Neoplasmer
- Neoplasmer efter sted
- Brystsygdomme
- Brystneoplasmer
- Lægemidlers fysiologiske virkninger
- Molekylære mekanismer for farmakologisk virkning
- Enzymhæmmere
- Antirheumatiske midler
- Antineoplastiske midler
- Immunsuppressive midler
- Immunologiske faktorer
- Tubulin modulatorer
- Antimitotiske midler
- Mitose modulatorer
- Antineoplastiske midler, Alkylering
- Alkyleringsmidler
- Myeloablative agonister
- Topoisomerase II-hæmmere
- Topoisomerasehæmmere
- Antibiotika, antineoplastisk
- Docetaxel
- Cyclofosfamid
- Doxorubicin
- Liposomal doxorubicin
Andre undersøgelses-id-numre
- GOG/2007-01
- 2007-005173-56
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .
Kliniske forsøg med Brystkræft
-
Cairo UniversityIkke rekrutterer endnu
-
Abouqir General HospitalAlexandria UniversityRekrutteringBreast Udseende Rekonstruktion DisproportionEgypten
-
Tianjin Medical University Cancer Institute and...Guangxi Medical University; Sun Yat-sen University; Chinese PLA General Hospital og andre samarbejdspartnereAfsluttetDen kliniske anvendelsesvejledning af Conebeam Breast CTKina
-
ETOP IBCSG Partners FoundationAfsluttetBreast Cancer Invasive NosItalien
-
Spanish Breast Cancer Research GroupHoffmann-La Roche; Roche Farma, S.AAfsluttetBreast Cancer Invasive NosSpanien
-
Ontario Clinical Oncology Group (OCOG)Afsluttet
-
Pomeranian Medical University SzczecinMaria Sklodowska-Curie National Research Institute of Oncology; Regional...UkendtBRCA1 mutation | Breast Cancer Invasive NosPolen
-
Aga Khan UniversityAfsluttetBrystkræft | Perforatorklap | Brysttumor | Oncoplasty | Breast-QPakistan
-
University Health Network, TorontoAfsluttetBreast Cancer Invasive Nos | Primær invasiv brystkræftCanada
-
KU LeuvenNovartisUkendtER Positive, HER2 Negative Breast Cancer NeoplasmaBelgien
Kliniske forsøg med Docetaxel, Liposomal doxorubicine and Cyclophosphamide
-
Duke UniversityUnited States Department of DefenseAfsluttetBrystkræft i tidligt stadiumForenede Stater
-
SanofiCancer International Research Group (CIRG)AfsluttetBrystkræftFrankrig, Hong Kong, Korea, Republikken, Den Russiske Føderation, Spanien, Forenede Stater, Argentina, Australien, Belgien, Bosnien-Hercegovina, Brasilien, Bulgarien, Canada, Kina, Colombia, Kroatien, Cypern, Tjekkiet, Egypten, Estlan... og mere
-
Second Affiliated Hospital, School of Medicine,...RekrutteringBrystkræft | Kemoterapeutisk toksicitetKina
-
SanofiAfsluttetBrystneoplasmerSpanien, Italien, Australien, Tjekkiet, Tyskland, Ungarn, Irland, Israel, New Zealand, Portugal, Slovenien, Slovakiet, Østrig, Sverige, Det Forenede Kongerige, Belgien, Brasilien, Chile, Danmark, Sydafrika, Schweiz
-
Peking Union Medical College HospitalAfsluttet
-
Shandong Cancer Hospital and InstituteUkendt
-
Case Comprehensive Cancer CenterNational Cancer Institute (NCI)Trukket tilbageBrystkræftForenede Stater
-
Zeneus PharmaUkendtMetastatisk brystkræftItalien
-
Fudan UniversityUkendtBrystneoplasmer | Kemoterapi | AdjuvansKina
-
Eastern Cooperative Oncology GroupNational Cancer Institute (NCI); Cancer and Leukemia Group B; North Central... og andre samarbejdspartnereAfsluttet